Systemic Anti-Cancer Therapy Regimen Library
Lymphoma Regimens
Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.
Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.
Published
Name | Version | Date |
---|---|---|
LYM - GCD [gemcitabine, cARBOplatin and dexamethasone] | 1.0.0 | 21/06/2023 |
LYM - GDP [gemcitabine, dexamethasone and cISplatin] | 1.0.0 | 21/06/2023 |
LYM - GemOx [gemcitabine and oxaliplatin] | 1.0.0 | 02/08/2023 |
LYM - PEP-C [prEDNISone, CYCLOPHOSPHamide, etoposide and procarbazine] | 1.0.0 | 19/06/2023 |
LYM - vinORELBine and gemcitabine | 2.0.0 | 23/10/2023 |
LYM Relapsed - DHAC [dexamethasone, high dose cytarabine and cARBOplatin] | 1.0.0 | 28/07/2023 |
LYM Relapsed - DHAP [dexamethasone, high dose cytarabine and cISplatin] | 1.0.0 | 03/10/2023 |
LYM Relapsed - GIVE [filgrastim, IFOSFamide, etoposide and epirubicin] | 1.0.0 | 03/10/2023 |
LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide] | 2.0.0 | 28/07/2023 |
LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing] | 1.0.0 | 12/08/2023 |
Hodgkin lymphoma Regimens
Published
Name | Version | Date |
---|---|---|
LYM HL Advanced - ChIVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone] | 1.0.0 | 19/09/2023 |